• 1
    Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 4369
  • 2
    Bates TS, Wright MP, Gillatt DA. Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-male questionnaire. Eur Urol 1998; 33: 1659
  • 3
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 97580
  • 4
    Scardino PT & Carlton CE. Combined interstitial and external irradiation for prostate cancer. In JavadpourN ed. Principles of Management of Urological Cancer. Baltimore: Williams and Wilkins, 1983: 392408
  • 5
    Whitmore WF Jr, Hilaris B, Grabstald H. Retropubic implantation of iodine125 in the treatment of prostatic cancer. J Urol 1972; 108: 91820
  • 6
    Zelefsky MJ & Whitmore WF Jr. Long-term results of retropubic permanent 125-iodine implantation of the prostate for clinically localised prostatic cancer. J Urol 1997; 158: 2330
  • 7
    Puthawala A, Syed AM, Tansey L. Temporary iridium-192 implant in the management of carcinoma of the prostate. Endocurietherapy Hypothermia Oncol 1985; 1: 2533
  • 8
    Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I. Transperineal iodine-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130: 2836
  • 9
    Anderson LL. Spacing nomogram for interstitial implants of I-125 seeds. Med Phys 1976; 3: 4851
  • 10
    Blasko JC, Ragde H, Grimm PD et al. Transperineal ultrasound guided palladium−103 brachytherapy for prostate carcinoma J Urol 1995; 153: 385(A)
  • 11
    Gore RM & Moss AA. Value of computed tomography in interstitial 125–I brachytherapy of prostatic carcinoma. Radiology 1983; 146: 4538
  • 12
    Kaye KW, Olson DJ, Lightner DJ, Payne JT. Improved technique for prostate seed implantation. Combined ultrasound and fluoroscopic guidance. J Endourol 1992; 6: 6166
  • 13
    Wallner KE, Chiu-tsao S, Roy J et al. A new device to stabilise templates for transperineal I-125 implants. Int J Radiat Oncol Biol Phys 1991; 20: 10757
  • 14
    Stock RG, Stone NM, Wesson MF et al. A modified technique allowing interactive ultrasound–guided 3-dimensional transperineal prostate implantation. Int J Rad Oncol Biol Phys 1995; 32: 21925
  • 15
    Hanks GC, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose–response studies. Int J Radiat Oncol Biol Phys 2000; 46: 82332
  • 16
    Komaki R, Mountain CF, Holbert JM. Superior sulcus tumours; treatment selection and results for 85 patients without metastasis at presentation. Int J Radiat Oncol Biol Phys 1990; 19: 316
  • 17
    Chadha M. Stage IIB carcinoma of the cervix managed with radiation therapy: An analysis of prognostic factors. Endocurietherapy Hyperthermia Oncol 1988; 4: 21928
  • 18
    Ling C. Permanent implants using Au198, 103Pd and 125I. Radiobiological considerations based on a linear quadratic model. Int J Radiat Oncol Biol Phys 1992; 23: 817
  • 19
    Dale RG. Radiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. Br J Radiol 1989; 62: 2414
  • 20
    Ragde H, Blasko JC, Grimm PD et al. Brachytherapy for clinically localised prostate cancer: results at 7- and 8-year follow up. Seminars Surg Oncol 1997; 13: 43843
  • 21
    Duchesne G & Peters L. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1999; 44: 7478
  • 22
    Dicker AP, Lin CC, Leeper DB, Waterman F. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I, based on radiobiological effectiveness and dosimetry. Semin Urol Oncol 2000; 18: 1529
  • 23
    Cha CM, Potters L, Ashley R et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999; 45: 3915
  • 24
    Gelblum DY, Potters L, Ashley R. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999; 45: 5967
  • 25
    Grimm PD, Blasko JC, Ragde H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer. Technical concepts in planning, operative technique, and evaluation. Urol Clin N Am 1994; 2: 11325
  • 26
    Amdur R, Gladstone D, Leopold K, Harris R. Prostate seed implant quality assessment using MR and CT image fusion. Int J Radiat Oncol Biol Phys 1999; 43: 6772
  • 27
    Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 83950
  • 28
    Cox J, Grignon D, Kaplan R et al. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 103541
  • 29
    Cavanagh W, Blasko JC, Grimm PD, Sylvester JE. Transient elevation of serum prostate specific antigen following 125I–103Pd brachytherapy for localised prostate cancer. Semin Urol Oncol 2000; 18: 1605
  • 30
    Catalona WJ & Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 183742
  • 31
    Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomical radical prostatectomy. Urol Clin North Am 1993; 20: 71325
  • 32
    Hanks GE. The case for external beam treatment of early-stage prostate cancer. Urology 2000; 55: 3015
  • 33
    Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ. Retrospective comparison of radical retropubic prostatectomy and 125 iodine brachytherapy for localized prostate cancer. J Urol 1999; 161: 12125
  • 34
    Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 18027
  • 35
    Ragde H, Elgamal AA, Snow PB. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localised, low to high grade Gleason prostate carcinoma. Cancer 1998; 83: 8981001
  • 36
    Grado GL, Larson TR, Balch CS et al. Actuarial disease free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998; 42: 28996
  • 37
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J 1999; 5: 3016
  • 38
    Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner K. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 12616
  • 39
    Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1–2 prostate tumours in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000; 48: 1117
  • 40
    Grimm P, Blasko J, Sylvester J, Meier R, Cavanagh W. 10 year biochemical (PSA) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 3140
  • 41
    Ragde H, Kobb L, Elgamal A, Grado G, Nadir B. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years observed follow up. Cancer 2000; 89: 13541DOI: 10.1002/1097-0142(20000701)89:1<135::aid-cncr18>;2-#
  • 42
    Blasko J, Grimm P, Sylvester J, Cavanagh W. The role of external beam radiotherapy with 125I/103Pd brachytherapy for prostate cancer. Radiother Oncol 2000; 57: 2738
  • 43
    Blasko J. Brachytherapy. Urology 2000; 55: 3068
  • 44
    Sylvester J, Blasko JC, Grimm PD et al. Neoadjuvant ablation combined with external-beam radiation therapy and permanent interstitial brachytherapy boost in localized prostate cancer. Molec Urol 1999; 3: 2316
  • 45
    D'Amico AV, Wittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 96974
  • 46
    Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 2000; 47: 12936
  • 47
    Prestidge BR, Haok DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Post-treatment biopsy results following interstitial brachytherapy in early stage prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 319
  • 48
    Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of I-125 implantation for localized prostate cancer using percutaneous approach. J Urol 1995; 153: 10205
  • 49
    Stock RG & Stone NN. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Sem Surg Oncol 1997; 13: 45460
  • 50
    Lee WR, DeGuzman AF, Bare RL, Marshall MG, McCullough DL. Post implant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 2000; 46: 838
  • 51
    Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998; 41: 1018
  • 52
    Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160: 137982
  • 53
    Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 1997; 137: 1138
  • 54
    Beyer DC & Priestley JB. Biochemical and disease free survival following I-125 prostate implantation. Int J Radiat Oncol Biol Phys 1997; 37: 55963
  • 55
    Wallner K, Roy J, Zelefsky M et al. Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 1994; 30: 4059
  • 56
    Wallner K, Roy S, Harrison L. Tumour control and morbidity following I-125 prostate implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996; 14: 44953
  • 57
    Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Rad Oncol Invest 1998; 6: 13541
  • 58
    Brown D, Colonias A, Miller R et al. Urinary morbidity with a modified peripheral loading technique of transperineal 125, I prostate implantation. Int J Radiat Ocol Biol Phys 2000; 47: 35360
  • 59
    Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 347: 1218
  • 60
    Ragde H, Blasko JC, Grimm PD et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997; 80: 44252DOI: 10.1002/(sici)1097-0142(19970801)80:3<442::aid-cncr12>;2-x
  • 61
    Stock RG, Stone NN, Yeghiayan P. Neoadjuvant androgen suppression and permanent radioactive seed implantation in the treatment of stage T1–T2 prostate cancer. Mol Urol 1998; 2: 1216
  • 62
    Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF. Neoadjuvant hormonal down-sizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13: 815
  • 63
    Shearer RJ, Davies JH, Gelister JS, Dearnaley DP. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992; 62: 5214
  • 64
    Yang FE, Chen GT, Ray P et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 100917
  • 65
    Bolla M, Gonzalez D, Padraig W et al. Improved survival in patients with clinically advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med 1997; 337: 295300
  • 66
    Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 24752
  • 67
    Stock RG, Stone NN, De Wyngaert JK, Lavagnini P, Unger PD. Prostate specific antigen findings and biopsy results following interactive ultrasound-guided transperineal brachytherapy early stage prostate carcinoma. Cancer 1996; 77: 238692
  • 68
    Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Sem Radiat Oncol 1993; 3: 2409
  • 69
    Arterbery VE, Wallner K, Roy J et al. Short term morbidity from CT-planned transperineal I-125 prostate implants. Int J Radiat Oncol Biol Phys 1993; 25: 6617
  • 70
    Arterbery VE, Frazier A, Dalmia P, Siefer J, Lutz M, Porter A. Quality of life after permanent prostate implant. Semin Surg Oncol 1997; 13: 4614DOI: 10.1002/(sici)1098-2388(199711/12)13:6<461::aid-ssu11>;2-w
  • 71
    Zelefsky MJ, Wallner KE, Ling CC et al. Comparison of the 5 year outcome and morbidity of 3-dimensional conformal radiotherapy versus transperineal permanent Iodine-125 implantation for early-stage prostate cancer. J Clin Oncol 1999; 17: 51722
  • 72
    Merrick GS, Butler WM, Lief JH, Stipetich RL, Abel LJ, Dorsey AT. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology 1999; 53: 11126
  • 73
    Dicker AP, Zelefsky MJ, Leibel SA et al. Risk factors for impotence in patients with carcinoma of the prostate treated with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32 (Suppl.): 191
  • 74
    Stone NN & Stock RG. Prostate brachytherapy; treatment strategies. J Urol 1999; 162: 4216
  • 75
    Gelbulm DY & Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48: 11924
  • 76
    Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal multi-varied quality of life analysis from the cancer of the prostate strategic research endeavour. J Urol 2000; 164: 19737
  • 77
    Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality off life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000; 163: 85162
  • 78
    Krupski T, Petroni GR, Bissonett EA. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localised prostate cancer. Urology 2000; 55: 73642DOI: 10.1016/s0090-4295(99)00597-x
  • 79
    Talcott J, Clark J, Stark P, Mitchell SP. Long term treatment related complications of brachytherapy for early prostate cancer: a survey of treated patients. Am Soc Clin Oncol Progr Proc 1999; 18: 311
  • 80
    Lee WR, McQuelon RP, Case DL, DeGuzman AF, McCullough DL. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localised prostate cancer. J Urol 1999; 162: 4036


  1. Authors

S.E.M. Langley, MS, FRCS(Urol), Consultant Urological Surgeon.

R. Laing, MRCP, FRCR, Consultant Clinical Oncologist.


radical prostatectomy.